Long-awaited outcomes data of transcatheter edge-to-edge procedures to repair patients’ leaky mitral valves revealed the minimally invasive procedure to be safe and effective in nearly 90% of patients, according to Cedars-Sinai physician-scientists.

news, journals and articles from all over the world.
Long-awaited outcomes data of transcatheter edge-to-edge procedures to repair patients’ leaky mitral valves revealed the minimally invasive procedure to be safe and effective in nearly 90% of patients, according to Cedars-Sinai physician-scientists.
Noel Bairey Merz, MD, professor of cardiology and the director of the Barbra Streisand Women’s Heart Center in the Smidt Heart Institute, will receive the 2023 Master of the ACC Award from the American College of Cardiology (ACC) in honor of her pioneering contributions to the cardiovascular profession.
Experts from the Smidt Heart Institute at Cedars-Sinai, California’s premier cardiology and heart surgery provider, will present innovative research findings and lead discussions on the latest high-impact medical breakthroughs during the American College of Cardiology (ACC) Annual Scientific Session & Expo March 4-6 in New Orleans.
Marking the five-year anniversary of the $50 million gift that named the Smidt Heart Institute, Cedars Sinai is highlighting major research breakthroughs and clinical innovations pioneered by one of the nation’s leading destinations for cardiac care.
Investigators from the Smidt Heart Institute at Cedars-Sinai have identified how biological pacemaker cells—cells that control your heartbeat—can “fight back” against therapies to biologically correct abnormal heartbeat rates.
Cardiologists, cardiothoracic surgeons and interventionalists from the Smidt Heart Institute at Cedars-Sinai are presenting an array of innovative research data and leading discussions on medical breakthroughs during the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Nov. 5-7.
Cedars-Sinai has been awarded a five-year, $8 million grant from California’s stem cell agency to launch an innovative new clinic that will expand patients’ access to stem cell and gene therapies, increase research and training in regenerative medicine, foster greater collaboration with eight similar clinics across the state and help educate the public about stem cell and related therapies.
Pioneering heart care is a tradition at Cedars-Sinai. It’s a tradition that took root in 1924, when Cedars-Sinai became home to the first electrocardiogram machine in Los Angeles.
Ser pionero en el cuidado del corazón es una tradición en Cedars-Sinai. Es una tradición que se arraigó en 1924, cuando Cedars-Sinai se convirtió en el hogar de la primera máquina de electrocardiograma en Los Ángeles.
The 2022 Annual Report from the Smidt Heart Institute at Cedars-Sinai is available now, detailing the latest research and medical achievements by the expert team ranked No. 1 for cardiology and cardiac surgery in California by U.S. News & World Report.
Peter Chen, MD, remembers those early days of March 2020 as one of swirling hyperactivity in the intensive care unit he leads at Cedars-Sinai. Chen and his team were struggling to respond to an emerging health crisis that was quickly growing into a global pandemic.
Lisa Stewart doesn’t dwell on the fact that she might be the first in the nation to undergo both mitral and tricuspid valve replacement procedures. She’s too busy counting her blessings.
Throughout the COVID-19 crisis, Cedars-Sinai employees have stepped-up and stepped-in to support patients and colleagues alike. And while there has been no shortage of selflessness, one group of volunteers shines a bright light on both the innovation and teamwork spurring from the past 10 months of treating the sickest of patients.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows. The findings, published in the peer-reviewed Journal of Extracellular Vesicles, could help develop new oral medications for treating patients with muscular dystrophy and heart failure.
Four of six critically ill COVID-19 (coronavirus) patients significantly improved after receiving an experimental therapeutic designed to reduce inflammation, a major cause of death from this disease, according to a case series published by Cedars-Sinai and Capricor Therapeutics. The four patients got well enough to be discharged from the hospital.